Knockdown of PARP6 or survivin promotes cell apoptosis and inhibits cell invasion of colorectal adenocarcinoma cells

Wang,Haipeng; Li,Shengguo; Luo,Xishun; Song,Zhike; Long,Xiangkai; Zhu,Xijia

doi:10.3892/or.2017.5441

Knockdown of PARP6 or survivin promotes cell apoptosis and inhibits cell invasion of colorectal adenocarcinoma cells

Authors:
- Haipeng Wang
- Shengguo Li
- Xishun Luo
- Zhike Song
- Xiangkai Long
- Xijia Zhu
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Guilin Medical University, Lingui, Guilin, Guangxi Zhuang Autonomous Region, Guangxi 541100, P.R. China
Published online on: February 14, 2017 https://doi.org/10.3892/or.2017.5441
Pages: 2245-2251

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal adenocarcinoma is the third most common cancer worldwide. PARP6, a novel member of the poly(ADP-ribose) polymerases (PARPs) and survivin, a member of the family of inhibitor of apoptosis (IAP) proteins are associated with a poor prognosis in various types of cancers. However, limited evidence exists regarding the interaction between PARP6 and survivin in colorectal adenocarcinoma. In the present study, we used the paired samples of 20 patients with colorectal adenocarcinoma to detect the expression of PARP6 and survivin in both tumor and adjacent normal colorectal mucosa. Their interaction and roles in cell viability, cell cycle, cell apoptosis and cell invasion were further investigated. Our results showed that both PARP6 and survivin exhibited higher expression in colorectal adenocarcinoma tissues and SW620 cells when compared with levels in adjacent non-tumor tissues and a normal colon cell line FHC. Co-immunoprecipitation assay showed that a significant correlation existed between PARP6 and survivin. We also showed that sole treatment of PARP6 siRNA or survivin siRNA partially inhibited the cell survival and invasion, induced cell G0/G1 arrest, and cell apoptosis at the early and late stages. The combined treatment of PARP6 siRNA and survivin siRNA suppressed the cell survival and cell invasion, further induced cell cycle phase G0/G1 arrest, and cell apoptosis at the early and late stages. Taken together, knockdown of PARP6 or survivin promotes cell apoptosis and inhibits the cell invasion of colorectal adenocarcinoma cells. A significant correlation exists between PARP6 and survivin, and both are promising targets for the development of new strategies for the diagnosis and treatment of advanced or metastatic colorectal adenocarcinoma.

View Figures

View References

1	Robbins AS, Siegel RL and Jemal A: Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol. 30:401–405. 2012. View Article : Google Scholar : PubMed/NCBI
2	Bultman SJ: Interplay between diet, gut microbiota, epigenetic events, and colorectal cancer. Mol Nutr Food Res. May 3–2016.(Epub ahead of print). doi: 10.1002/mnfr.201500902. PubMed/NCBI
3	Itatani Y, Kawada K, Inamoto S, Yamamoto T, Ogawa R, Taketo MM and Sakai Y: The role of chemokines in promoting colorectal cancer invasion/metastasis. Int J Mol Sci. 17:pii: E643. 2016. View Article : Google Scholar : PubMed/NCBI
4	Meads MB, Gatenby RA and Dalton WS: Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat Rev Cancer. 9:665–674. 2009. View Article : Google Scholar : PubMed/NCBI
5	Kraus WL: Transcriptional control by PARP-1: Chromatin modulation, enhancer-binding, coregulation, and insulation. Curr Opin Cell Biol. 20:294–302. 2008. View Article : Google Scholar : PubMed/NCBI
6	Clayton C and Hotz HR: Post-transcriptional control of PARP gene expression. Mol Biochem Parasitol. 77:1–6. 1996. View Article : Google Scholar : PubMed/NCBI
7	Hassa PO and Hottiger MO: The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 13:3046–3082. 2008. View Article : Google Scholar : PubMed/NCBI
8	Hakmé A, Wong HK, Dantzer F and Schreiber V: The expanding field of poly(ADP-ribosyl)ation reactions. ‘Protein Modifications: Beyond the Usual Suspects’ Review Series. EMBO Rep. 9:1094–1100. 2008. View Article : Google Scholar : PubMed/NCBI
9	Honda S, Minato M, Suzuki H, Fujiyoshi M, Miyagi H, Haruta M, Kaneko Y, Hatanaka KC, Hiyama E, Kamijo T, et al: Clinical prognostic value of DNA methylation in hepatoblastoma: Four novel tumor suppressor candidates. Cancer Sci. 107:812–819. 2016. View Article : Google Scholar : PubMed/NCBI
10	Gonçalves A, Sabatier R, Charafe-Jauffret E, Gilabert M, Provansal M, Tarpin C, Extra JM, Viens P and Bertucci F: Triple-negative breast cancer: Histoclinical and molecular features, therapeutic management and perspectives. Bull Cancer. 100:453–464. 2013.(In French). PubMed/NCBI
11	Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A and Azzariti A: Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol. 7:308–322. 2013. View Article : Google Scholar : PubMed/NCBI
12	Salemi M, Galia A, Fraggetta F, La Corte C, Pepe P, La Vignera S, Improta G, Bosco P and Calogero AE: Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue. Eur J Histochem. 57:e132013. View Article : Google Scholar : PubMed/NCBI
13	Qi G, Kudo Y, Tang B, Liu T, Jin S, Liu J, Zuo X, Mi S, Shao W, Ma X, et al: PARP6 acts as a tumor suppressor via downregulating Survivin expression in colorectal cancer. Oncotarget. 7:18812–18824. 2016.PubMed/NCBI
14	Tuncel H, Tanaka S, Oka S, Nakai S, Fukutomi R, Okamoto M, Ota T, Kaneko H, Tatsuka M and Shimamoto F: PARP6, a mono(ADP-ribosyl) transferase and a negative regulator of cell proliferation, is involved in colorectal cancer development. Int J Oncol. 41:2079–2086. 2012.PubMed/NCBI
15	Fragni M, Bonini SA, Stabile A, Bodei S, Cristinelli L, Simeone C, Zani D, Spano PF, Berruti A, Memo M, et al: Inhibition of survivin is associated with zoledronic acid-induced apoptosis of prostate cancer cells. Anticancer Res. 36:913–920. 2016.PubMed/NCBI
16	Wu J, Zhao S, Zhang J, Qu X, Jiang S, Zhong Z, Zhang F, Wong Y and Chen H: Over-expression of survivin is a factor responsible for differential responses of ovarian cancer cells to S-allylmercaptocysteine (SAMC). Exp Mol Pathol. 100:294–302. 2016. View Article : Google Scholar : PubMed/NCBI
17	Huang W, Mao Y, Zhan Y, Huang J, Wang X, Luo P, Li LI, Mo D, Liu Q, Xu H, et al: Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy. Oncol Lett. 11:723–730. 2016.PubMed/NCBI
18	Ma WH, Liu YC, Xue ML, Zheng Z and Ge YL: Downregulation of survivin expression exerts antitumoral effects on mouse breast cancer cells in vitro and in vivo. Oncol Lett. 11:159–167. 2016.PubMed/NCBI
19	Zhu J, Sun C, Wang L, Xu M, Zang Y, Zhou Y, Liu X, Tao W, Xue B, Shan Y, et al: Targeting survivin using a combination of miR 494 and survivin shRNA has synergistic effects on the suppression of prostate cancer growth. Mol Med Rep. 13:1602–1610. 2016.PubMed/NCBI
20	Wang H, Yang M, Xu J, Zou B, Zhou Q, Bian J and Wang X: Survivin mRNA-circulating tumor cells are associated with prostate cancer metastasis. Tumour Biol. 37:723–727. 2016. View Article : Google Scholar : PubMed/NCBI
21	Yang B, Huang J, Liu H, Guo W and Li G: miR-335 directly, while miR-34a indirectly modulate survivin expression and regulate growth, apoptosis, and invasion of gastric cancer cells. Tumour Biol. 37:1771–1779. 2016. View Article : Google Scholar : PubMed/NCBI
22	Wang TA, Zhang XD, Guo XY, Xian SL and Lu YF: 3-Bromopyruvate and sodium citrate target glycolysis, suppress survivin, and induce mitochondrial-mediated apoptosis in gastric cancer cells and inhibit gastric orthotopic transplantation tumor growth. Oncol Rep. 35:1287–1296. 2016.PubMed/NCBI
23	Zhang B, Leng C, Wu C, Zhang Z, Dou L, Luo X, Zhang B and Chen X: Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. Oncol Rep. 35:1807–1815. 2016.PubMed/NCBI
24	Li WL, Lee MR and Cho MY: The small molecule survivin inhibitor YM155 may be an effective treatment modality for colon cancer through increasing apoptosis. Biochem Biophys Res Commun. 471:309–314. 2016. View Article : Google Scholar : PubMed/NCBI
25	Steponaitis G, Skiriutė D, Kazlauskas A, Golubickaitė I, Stakaitis R, Tamašauskas A and Vaitkienė P: High CHI3L1 expression is associated with glioma patient survival. Diagn Pathol. 11:422016. View Article : Google Scholar : PubMed/NCBI
26	Qu Y, Gu C, Wang H, Chang K, Yang X, Zhou X, Dai B, Zhu Y, Shi G, Zhang H, et al: Diagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: Clinicopathological data from ethnic Chinese population. Sci Rep. 6:216772016. View Article : Google Scholar : PubMed/NCBI
27	Lee WK and Kang JS: Modulation of apoptosis and differentiation by the treatment of sulfasalazine in rabbit articular chondrocytes. Toxicol Res. 32:115–121. 2016. View Article : Google Scholar : PubMed/NCBI
28	Schreiber V, Dantzer F, Ame JC and de Murcia G: Poly(ADP-ribose): Novel functions for an old molecule. Nat Rev Mol Cell Biol. 7:517–528. 2006. View Article : Google Scholar : PubMed/NCBI